Business Wire

SES and AXESS Networks to Enable Smart Mining with O3b mPOWER

Share

SES and AXESS Networks (AXESS), a leading provider of satellite connectivity solutions, are accelerating digital transition of the mining industry with SES’s second-generation medium earth orbit (MEO) system O3b mPOWER, the two companies announced today. Under this multi-year, multi-million agreement, the mining sector users will be able to benefit from the cutting-edge low-latency Onshore Energy & Mining mPOWERED connectivity service.

SES’s Onshore Energy & Mining mPOWERED service will provide the highest throughput available from a satellite system and deliver dedicated and carrier-grade networks to AXESS’ customers reliably regardless of their remote locations. O3b mPOWER can deliver up to multiple gigabits per second per site, enabling AXESS’ customers to accelerate the digitalisation of their operations and sites globally, boosting profitability through access to new applications and efficiency, as well as improving staff safety and welfare. SES’s second-generation MEO connectivity service also brings the Cloud closer to the end customers and can enable edge computing to support the use of 5G and IoT in the mining industry.

Simon GattySaunt, Vice President of Networks Sales, Europe, at SES, said, “Transition towards smart mining is already turbocharging profits, and revolutionising industry’s environmental and societal impact. We are proud of the success our partnership with AXESS has already had in facilitating this change, thanks to our multi-orbit GEO and MEO network, and are excited to further accelerate it with the O3b mPOWER service.”

Guido Neumann, President AXESS EMEA said, “This agreement builds on a long and successful relationship with SES, which has helped us to provide our customers with the best-in-class, reliable and resilient connectivity for their operations. As we are seeing a considerable uptake in demand for the carrier-grade solutions globally, but especially in the EMEA and APAC region, we are honoured to play an active role in scaling the digital transition in the mining sector through introducing O3b mPOWER and the Onshore Energy & Mining mPOWERED service.”

Follow us on:
TwitterFacebook | YouTubeLinkedInInstagram
Read our Blogs >
Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over ~8,200 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com

About AXESS Networks

AXESS Networks (AXESS)is a global leader in satellite-based solutions that manages the entire satellite communications value chain with engineering solutions tailored to its customers’ requirements. AXESSwas founded in 2019 via the merger of CETel and Axesat, two well-established companies in Europe and Latin America. AXESS operates and owns Teleports in Germany, Colombia, Mexico, Peru, Saudi Arabia and the United Arab Emirates (UAE). It provides turnkey solutions for the individual requirements of its clients from a broad range of industries: Corporate, Energy, Maritime, Telcos, Government, Humanitarian Services and Media. More than 200 AXESS employees serve over 800 clients in 50 countries with deep market understanding. AXESS was awarded as the Independent Teleport Operator of the Year by the WTA (World Teleport Association) in 2021. Further information is available at: www.axessnet.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Suzanne Ong
External Communications, SES
+352 710 725 500
suzanne.ong@ses.com

Corinne Effinger
Communications Manager, AXESS EMEA
+49 2295 90878 38
corinne.effinger@axessnet.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 18:27:00 CEST | Press release

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r

Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 18:00:00 CEST | Press release

Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with

Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private Companies18.8.2022 15:49:00 CEST | Press release

Veristat, global experts in clinical development, registration and post-marketing solutions proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has significantly expanded in size, geographic reach and service offering to swiftly guide novel therapies through their clinical development process to regulatory approval and commercialization. Veristat’s team of scientific experts works collaboratively with clients in the biotech and pharmaceutical industries to overcome the many challenges associated with bringing to market products that address current medical shortcomings and maintain their good standing. “Being recognized as one of America’s Fastest-Growing Private Companies is a testament to Veristat’s ability to deliver innovative solutions, bold thinking and versatile engagement models to our clients,” stated Patrick Flanagan, Chief Executive Of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom